Referencias►
1.
Erdelmeier CAJ. Hyperforin, possibly the major non-nitrogenous secondary metabolite of
Hypericum perforatum
L.
Pharmacopsychiatry. 1998;31(suppl 1):2 - 6.
2.
Schulz V. Hyperforin-Werte keinesfalls nur "Spuren."
Dtsch Apoth Ztg. 1998;138:65. Cited by: Chatterjee S, Noldner M, Koch E, et al. Antidepressant activity of
Hypericum perforatum
and hyperforin: the neglected possibility.
Pharmacopsychiatry. 1998;31(suppl 1):7 - 15.
3.
Suzuki O, Katsumata Y, Oya M, et al. Inhibition of monoamine oxidase by hypericin.
Planta Med. 1984;50:272 - 274.
4.
Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract.
J Geriatr Psychiatr Neurol. 1994;7(suppl 1):S57 - S59.
5.
Thiede HM, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin.
J Geriatr Psychiatr Neurol. 1994;7(suppl 1):S54 - S56.
6.
Muller WE, Rossol R. Effects of hypericum extract on the expression of serotonin receptors
. J Geriatr Psychiatry Neurol . 1994;7(suppl 1):S63 - S64.
7.
Muller WE, Kasper S, Volz HP, et al. Hypericum extract (LI160) as an herbal antidepressant.
Pharmacopsychiatry.
1997;30(suppl 2):71 - 134.
8.
Muller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract.
Pharmacopsychiatry. 1998;31(suppl 1):16 - 21.
9.
Ghattacharya SK, Chakrabareti A, Chatterjee SS. Activity profiles of two hyperforin-containing hypericum extracts in behavioural models.
Pharmacopsychiatry,
1998;31(suppl):22 - 29.
10.
Laakmann G, Schle C, Baghai T, et al. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.
Pharmacopsychiatry. 1998;31(suppl):54 - 59.
11.
Dimpfel W, Schober F, Mannel M. Effects of a methanolic extract and a hyperforin-enriched CO2 extract of St. John's wort (
Hypericum perforatum) on intracerebral field potentials in the freely moving rat (Tele-Stereo-EEG).
Pharmacopsychiatry. 1998;31(suppl 1):30 - 35.
12.
Butterweck V, Jurgenliemk G, Nahrstedt A, et al. Flavonoids from
Hypericum perforatum
show antidepressant activity in the forced swimming test.
Planta Med.
2000;66:3 - 6.
13.
Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression.
Int Clin Psychopharmacol.
2000;15:61 - 68.
14.
Schrader E, Meier B, Brattstrom A. Hypericum treatment of mild-moderate depression in a placebo-controlled study: a prospective, double-blind, randomized, placebo-controlled, multicentre study.
Hum Psychopharmacol.
1998;13:163 - 169.
15.
Schulz H, Jobert M. The influence of hypericum extract on the sleep EEG in older volunteers [in German; English abstract].
Nervenheilkunde. 1993;12:323 - 327.
16.
Sindrup SH, Madsen C, Bach FW, et al. St. John's wort has no effect on pain in polyneuropathy.
Pain. 2001;91:361 - 365.
17.
Gulick R, McAuliffe V, Holden-Wiltse J, et al. Phase I studies of hypericin, the active compound in St. John's wort, as an antiretroviral agent in HIV-infected adults.
Ann Intern Med.
1999;130:510 - 514.
18.
Schempp CM, Pelz K, Wittmer A, et al. Antibacterial activity of hyperforin from St John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria.
Lancet.
1999;353:2129.
19.
Stevinson C, Ernst E. A pilot study of
Hypericum perforatum
for the treatment of premenstrual syndrome.
BJOG.
2000;107:870 - 876.
20.
Grube B, Walper A, Wheatley D. St. John's Wort extract: efficacy for menopausal symptoms of psychological origin.
Adv Ther.
1999;16:177 - 186.
21.
Hansgen KD, Vesper J, Ploch M. Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160.
J Geriatr Psychiatry Neurol. 1994;7(suppl 1):S15 - S18.
22.
Laakmann G, Schle C, Baghai T, et al. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.
Pharmacopsychiatry. 1998;31(suppl):54 - 59.
23.
Schrader E, Meier B, Brattstrom A. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study.
Hum Psychopharmacol.
1998;13:163 - 169.
24.
Linde K, Ramirez G, Mulrow CD, et al. St. John's wort for depression - An overview and meta-analysis of randomised clinical trials.
BMJ. 1996;313:253 - 258.
25.
Ernst E. St. John's wort, an anti-depressant? A systematic, criteria-based review.
Phytomedicine. 1995;2:67 - 71.
26.
Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks.
BMJ. 1999;319:1534 - 1539.
27.
Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John's wort in major depression: a randomized controlled trial.
JAMA. 2001;285:1978 - 1986.
28.
Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial.
Pharmacopsychiatry. 2001;34:96 - 103.
29.
Hansgen KD, Vesper J. Antidepressant efficacy of a high-dose hypericum extract [translated from German].
MMW Munch Med Wochenschr. 1996;138:29 - 33.
30.
Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John's wort in major depression: a randomized controlled trial.
JAMA. 2001;285:1978 - 1986.
31.
Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild - moderate depression.
Int Clin Psychopharmacol.
2000;15:61 - 68.
32.
Harrer G, Schmidt U, Kuhn U, et al. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine.
Arzneimittelforschung.
1999;49:289 - 296.
33.
Brenner R, Azbel V, Madhusoodanan S, et al. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study.
Clin Ther.
2000;22:411 - 419.
34.
Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks.
BMJ.
1999;319:1534 - 1539.
35.
Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10.
Pharmacopsychiatry. 1997;30(suppl 2):81 - 85.
36.
Schulz V, Hansel R, Tyler VE.
Rational Phytotherapy: A Physicians' Guide to Herbal Medicine. 3rd ed. Berlin, Germany: Springer-Verlag; 1998:59.
37.
Linde K, Ramirez G, Mulrow CD, et al. St. John's wort for depression - An overview and meta-analysis of randomised clinical trials.
BMJ. 1996;313:253 - 258.
38.
Ernst E. St. John's wort, an anti-depressant? A systematic, criteria-based review.
Phytomedicine. 1995;2:67 - 71.
40.
Sindrup SH, Madsen C, Bach FW, et al. St. John's wort has no effect on pain in polyneuropathy.
Pain. 2001;91:361 - 365.
41.
Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression.
Int Clin Psychopharmacol. 2000;15:61 - 68.
42.
Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial.
BMJ. 2000;321:536 - 539.
43.
Woelk H, Burkard G, Grunwald J. Benefits and risks of the hypericum extract LI 160: Drug monitoring study with 3,250 patients.
J Geriatr Psychiatr Neurol. 1994;7(suppl 1):S34 - S38.
44.
Hubner WD, Arnoldt KH. St John's Wort: a one year treatment study [in German; English abstract].
Z Phytother.
2000;21:306 - 310.
45.
De Smet PA, Nolen WA. St. John's wort as an anti-depressant.
BMJ. 1996;3:241 - 242.
46.
Schulz V, Hansel R, Tyler VE.
Rational Phytotherapy: A Physicians' Guide to Herbal Medicine. 3rd ed. Berlin, Germany: Springer-Verlag; 1998:56.
47.
Brockmoller J, Reum T, Bauer S, et al. Hypericin and pseudohypericin: Pharmacokinetics and effects on photosensitivity in humans.
Pharmacopsychiatry. 1997;30(suppl 2):94 - 101.
48.
Lane-Brown MM. Photosensitivity associated with herbal preparations of St John's wort (Hypericum perforatum) [letter].
Med J Aust. 2000;172:302.
49.
Mirossay A, Mirossay L, Tothova J, et al. Potentiation of hypericin and hypocrellin-induced phototoxicity by omeprazole.
Phytomedicine.
1999;6:311 - 317.
50. Roberts J. Presentation at the 1999 Meeting of the American Society for Photobiology.
51.
DeMott K. St. John's wort tied to serotonin syndrome.
Clinical Psychiatry News. 1998;26:28.
52.
Gordon JB. SSRIs and St. John's wort: Possible toxicity?
Am Fam Physician. 1998;57:950, 953.
53.
Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly.
J Geriatr Psychiatry Neurol. 1999;12:7 - 10.
54.
Mason BJ, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline coadministration.
Ann Pharmacother.
1997;31:175 - 177.
55.
Hernandez AF, Montero MN, Pla A, et al. Fatal moclobemide overdose or death caused by serotonin syndrome?
J Forensic Sci.
1995;40:128 - 130.
56.
Jobst KA, McIntyre M, St. George D, et al. Safety of St John's wort
(Hypericum perforatum).Lancet.
2000,355:575.
57.
Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John's wort.
Lancet.
2000;355:548.
58.
Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's wort.
Lancet.
2000;355:547.
59.
Baker RK, Brandt TL, Siegel D, et al. Inhibition of human DNA topoisomerase IIalpha by the naphtha-dianthrone, hypericin.
Proc Am Assoc Cancer Res.
1998;39:422.
60.
Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort
(Hypericum perforatum).Clin Pharmacol Ther.
1999;66:338 - 345.
61.
Maurer A. Interaction of St. John's wort extract with phenprocoumon.
Eur J Clin Pharmacol.
1999;55:A22. (Abstract 79).
62.
Nebel A, Baker RK, Schneider BJ, et al. Potential metabolic interaction between St. John's wort and theophylline.
Ann Pharmacother.
1999;33:502.
63.
De Smet PA, Touw DJ. Safety of St. John's wort.
Lancet.
2000;355:575 - 576.
64.
Breidenbach TH, Hoffmann MW, Becker TH, et al. Drug interaction of St John's wort with ciclosporin.
Lancet.
2000;355:1912.
65.
Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St. John's wort and cyclosporine.
Ann Pharmacother.
2000;34:1013 - 1016.
66.
Dresser GK, Schwarz UI, Wilkinson GR, et al. St. John's wort induces intestinal and hepatic CYP3A4 and P-glycoprotein in healthy volunteers [abstract].
Clin Pharmacol Ther. 2001;69:P23.
67. Abul-Ezz SR, Barone GW, Gurley BJ, et al. Effect of herbal supplements on cyclosporine blood levels and associated acute rejection. Presented at: 33rd Annual Meeting of the American Society of Nephrology, Renal Week 2000. October 11 - 16, 2000. Toronto, Canada.
68.
Jobst KA, McIntyre M, St. George D, et al. Safety of St John's wort
(Hypericum perforatum).Lancet.
2000;355:575.
69.
Rayburn WF, Gonzalez CL, Christensen HD, et al. Effect of prenatally administered hypericum (St John's wort) on growth and physical maturation of mouse offspring.
Am J Obstet Gynecol.
2001;184:191 - 195.
70.
Miskovsky P, Chinsky L, Wheeler GV, et al. Hypericin site specific interactions within polynucleotides used as DNA model compounds.
J Biomol Struct Dyn.
1995;13:547 - 552.
71.
Nierenberg AA, Burt T, Matthews J, et al. Mania associated with St. John's wort.
Biol Psychiatry. 1999;46:1707 - 1708.
72.
Barbenel DM, Yusufi B, O'Shea D, et al. Mania in a patient receiving testosterone replacement postorchidectomy taking St John's wort and sertraline.
J Psychopharmacol. 2000;14:84 - 86.
73.
Ellis KA, Stough C, Vitetta L, et al. An investigation into the acute nootropic effects of
Hypericum perforatum
L. (St. John's Wort) in healthy human volunteers.
Behav Pharmacol.
2001;12:173 - 182.
74.
Parker V, Wong AH, Boon HS, et al. Adverse reactions to St John's Wort.
Can J Psychiatry.
2001;46:77 - 79.
75.
Ondrizek RR, Chan PJ, Patton WC, et al. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid.
Fertil Steril.
1999;71:517 - 522.
76.
Suzuki O, Katsumata Y, Oya M, et al. Inhibition of monoamine oxidase by hypericin.
Planta Med. 1984;50:272 - 274.
77.
Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract.
J Geriatr Psychiatr Neurol. 1994;7(suppl 1):S57 - S59.
78.
Thiede HM, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin.
J Geriatr Psychiatr Neurol. 1994;7(suppl 1):S54 - S56.
79.
Laird RD, Webb M. Psychotic episode during use of St. John's wort.
J Herbal Pharmacother. 2001;1:81 - 87.
80.
Mai I, Kruger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John's wort (
Hypericum perforatum) with the immunosuppressant cyclosporin.
Int J Clin Pharmacol Ther. 2000;38:500-502.
81.
Sugimoto Ki K, Ohmori M, Tsuruoka S, et al. Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin.
Clin Pharmacol Ther. 2001;70:518 - 524]
82.
Roots J, et al. Interaction of a herbal extract from St. John's wort with amitryptyline and its metabolites (Abstract).
Clin Pharmacol Ther
2000;67:159
83.
Schempp CM, et al. Single-dose and steady-state administration of
Hypericum perforatum
extract (St. John's Wort) does not influence skin sensitivity to UV radiation, visible light, and solar-simulated radiation.
Arch Dermatol
2001;137:512-513
84.
Lane-Brown MM. Photosensitivity associated with herbal preparations of St John's wort (
Hypericum perforatum) [letter].
Med J Aust.
2000;172:302.
85.
Hypericum Depression Trial Study Group. Effect of
Hypericum perforatum
(St. John's wort) in major depressive disorder: a randomized controlled trial.
JAMA.
2002;287:1807-1814.
86.
Hubner WD, Kirste T. Experience with St John's Wort (
Hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances.
Phytother Res. 2001;15:367 - 370.
87.
de Maat MM, Hoetelmans RM, Mathot RA, et al. Drug interaction between St. John's wort and nevirapine [letter].
AIDS. 2001;15:420 - 421.
88. Gorski JC, Hamman MA, Wang Z, et al. The effect of St. John's Wort on the efficacy of oral contraception. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, March 24-27, 2002, Atlanta, GA; abstract MPI-80.
89.
Lecrubier Y, Clerc G, Didi R, et al. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial.
Am J Psychiatry.
2002;159:1361-1366.
90.
Behnke K, Jensen GS, Graubaum HJ, et al.
Hypericum perforatum
versus fluoxetine in the treatment of mild to moderate depression.
Adv Ther. 2002;19:43-52.
91.
van Gurp G, Meterissian GB, Haiek LN, et al. St John's wort or sertraline? Randomized controlled trial in primary care.
Can Fam Physician. 2002;48:905-912.
92.
Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's Wort on irinotecan metabolism.
J Natl Cancer Inst.
2002;94:1247-1249.
93.
Hennessy M, Kelleher D, Spiers JP, et al. St. John's Wort increases expression of P-glycoprotein: implications for drug interactions.
Br J Clin Pharmacol. 2002;53:75-82.
94.
Schultz V. Clinical trials with
hypericum
extracts in patients with depression--results, comparisons, conclusions for therapy with antidepressant drugs.
Phytomedicine. 2002;9:468-474.
95.
Johne A, Schmider J, Brockmoller J, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort
(Hypericum perforatum).
J Clin Psychopharmacol.
2002;22:46-54.
96.
Patel S, Robinson R, Burk M. Hypertensive crisis associated with St. John's Wort.
Am J Med. 2002;112:507-508.
97.
Bennet DA, Phyun L, Pok JF, et al. Neuropharmacology of St. John's Wort (
Hypericum).
Ann Pharmacother. 1998;32:1201-1208.
98.
Martinez B, Kasper S, Ruhrmann S, et al. Hypericum in the treatment of seasonal affective disorders.
J Geriatr Psychiatr Neurol. 1994;7(Suppl 1):S29 - S33.
99.
Wheatley D. Hypericum in seasonal affective disorder (SAD).
Curr Med Res Opin. 1999;15:33 - 37.
100.
Schempp M, Hezel S, Simon C. Topical treatment of Atopic dermatitis with Hypericum creamA randomised, placebo-controlled, double-blind half-side comparison study.
Hautarzt. 2003;54:248 - 253.
101.
Crowe S, McKeating K. et al. Delayed emergence and St. John's wort.
Anesthesiology. 2002;96:1025 - 1027.
